Novo Nordisk A/S (NYSE:NVO) Shares Sold by Birch Capital Management LLC

Birch Capital Management LLC lessened its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 3.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 134,623 shares of the company’s stock after selling 5,510 shares during the quarter. Novo Nordisk A/S makes up approximately 5.8% of Birch Capital Management LLC’s investment portfolio, making the stock its 4th largest position. Birch Capital Management LLC’s holdings in Novo Nordisk A/S were worth $11,580,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in NVO. Natixis Advisors LLC lifted its holdings in Novo Nordisk A/S by 2.7% during the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after purchasing an additional 80,070 shares during the last quarter. Versant Capital Management Inc bought a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $86,000. Norman Fields Gottscho Capital Management LLC grew its stake in shares of Novo Nordisk A/S by 45.3% in the fourth quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after acquiring an additional 19,870 shares in the last quarter. Zions Bancorporation N.A. increased its position in Novo Nordisk A/S by 57.0% during the third quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock worth $2,207,000 after acquiring an additional 6,726 shares during the period. Finally, Wealth Enhancement Advisory Services LLC raised its stake in Novo Nordisk A/S by 14.8% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock worth $34,463,000 after purchasing an additional 37,346 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Price Performance

NVO stock traded down $2.03 during trading on Tuesday, reaching $83.00. 6,231,371 shares of the company were exchanged, compared to its average volume of 6,209,503. The company has a 50-day moving average of $102.51 and a two-hundred day moving average of $120.68. The company has a market capitalization of $372.47 billion, a price-to-earnings ratio of 26.86, a P/E/G ratio of 1.37 and a beta of 0.45. Novo Nordisk A/S has a twelve month low of $81.50 and a twelve month high of $148.15. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75.

Analyst Ratings Changes

Several research analysts have recently commented on NVO shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BMO Capital Markets reduced their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday. Finally, BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $140.20.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.